Affiliations of authors: Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia (RJM, DRE, GGG); School of Population Health, University of Melbourne, Melbourne, Australia (RJM); Centre for Genetic Epidemiology, University of Melbourne, Melbourne, Australia (DRE, JLH, GGG)
Correspondence to: Graham G. Giles, PhD, Cancer Epidemiology Centre, Cancer Control Research Institute, The Cancer Council Victoria, 1 Rathdowne St., Carlton South VIC 3053, Australia (e-mail: graham.giles{at}cancervic.org.au).
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() |
---|
The Melbourne Collaborative Cohort Study recruited 41 528 people between 1990 and 1994 (1416) to investigate the role of nutritional and other lifestyle factors in cancer. The study was approved by The Cancer Council Victoria Human Research Ethics Committee, and written informed consent was obtained from all subjects. Subjects diagnosed with lymphohematopoietic malignancies before baseline (n = 105), with incomplete baseline measurements (n = 214), or who had either died, left Victoria, or had a diagnosis of lymphohematopoietic malignancies in the first 2 years of follow-up (n = 300) were excluded, leaving 40 909 people available for analysis.
Height, weight, and waist and hips circumferences were measured using standard procedures (17), and BMI and waist-to-hips ratios were computed. We used bioelectrical impedance analysis using a BIA-101A RJL system analyzer (RJL systems, Detroit, MI) to estimate fat-free mass (18). Fat mass (weight fat-free mass) and percent fat (fat mass divided by weight) were subsequently calculated. Information on country of birth, alcohol, smoking, physical activity, and highest level of education was obtained by structured interview. Vital status and place of residence were obtained from electoral rolls, electronic phone books, and death records until 31 December 2003. At this time, 721 people had left Victoria (1.7%) and 2681 (6.5%) had died.
Case patients were identified from notifications of diagnoses of malignant neoplasms of lymphatic and hematopoietic tissue (International Classification of Diseases 10th revision morphology codes 959998) to the population-based Victorian Cancer Registry. The main outcomes were myeloid leukemia and lymphoproliferative malignancies (and subgroups such as non-Hodgkin lymphoma [NHL], multiple myeloma, and lymphocytic leukemia).
Cox proportional hazards regression models, with age as the time axis (19), were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Tests based on Schoenfeld residuals and graphical methods using KaplanMeier curves (20) showed no evidence that proportional hazard assumptions were violated for any of the anthropometric measures. Because the hazard ratios from analyses excluding the first 2 years of follow-up were higher for myeloid leukemia than those without this exclusion, results presented are based on follow-up that began 2 years after baseline and ended at diagnosis of lymphohematopoietic malignancies or cancer of unknown primary site, death, the date last known to be in Victoria, or 31 December 2003, whichever came first.
Analyses were adjusted for country of birth (Australia and United Kingdom or Greece and Italy), sex, education, and smoking status. Adjustments for physical activity and alcohol consumption did not appreciably change the hazard ratios, so these variables were not included in final analyses. In a sensitivity analysis, all people diagnosed with any cancer (apart from the cancer of interest) were censored at diagnosis. This did not materially change the hazard ratios (data not shown).
Statistical analyses were performed using Stata/SE 8.2 (Stata Corporation, College Station, TX). All P values are two-sided, and P<.05 was considered as statistically significant.
The participants' demographic characteristics are shown in Table 1. Myeloid leukemia was positively associated with several aspects of body size (Table 2). Incidence was approximately five times higher for overweight and obese participants than for those with BMI less than 25 kg/m2 (HR = 5.3, 95% CI = 1.9 to 15.2 and HR = 5.0, 95% CI = 1.6 to 15.5, respectively). The hazard ratio for the highest tertile was 2.9 (95% CI = 1.4 to 6.1) for fat-free mass and 2.6 (95% CI = 1.2 to 5.6) for fat mass. Waist circumference was also associated with increased risk (per 10-cm increase HR = 1.35, 95% CI = 1.06 to 1.72; P = .02), but the relationship was not monotonic. Although hazard ratios were higher for chronic myeloid leukemia (CML) (data not shown), numbers were too small to perform formal statistical tests of homogeneity between CML and acute myeloid leukemia (AML). All hazards ratios for lymphoproliferative malignancies (and subgroups) were close to unity (Table 3 and Supplementary Tables 1 to 4 available at http://jncicancerspectrum.oxfordjourals.org/jnci/content/vol97/issue15).
|
|
|
The study had several strengths and some limitations. Because few participants had left Victoria during the follow-up period, follow-up was 98.3% complete. Another strength of the study was that direct measures of body size were taken at baseline. Issues concerning the measurement of fat-free mass and fat mass have been addressed elsewhere (16,21). In this study, measurement errors for fat-free mass and fat mass were generally small. To prevent a potential bias of altered body mass and composition that was due to undiagnosed disease, we excluded measurements made during the first 2 years of follow-up. However, we could not completely exclude patients with splenomegaly, which is commonly associated with myeloid leukemia, who could have consequently had a larger waist size prior to diagnosis. In addition, established etiologic exposures for lymphohematopoietic malignancies, such as radiation and benzene, were not recorded; therefore, we could not assess their possible impact. The major limitation of the study was the small number of case patients, leading to low statistical power for certain subgroup analyses.
Whether obesity is a risk factor for NHL remains uncertain. Some studies, including ours, have not shown any notable association (2,5,8,13), whereas others have described a positive association (1,9,10). There are reports (3,7,10,12) that obese persons are at an increased risk of multiple myeloma, although the associations have been generally weak, and we were unable to confirm this association.
Little has been reported on the association between leukemia and body size. Our finding that overweight and obese people are at higher risk than people of healthy weight of myeloid leukemia but not chronic lymphocytic leukemia (CLL) is concordant with the Iowa Women's Health Study (6), which showed an association between BMI and AML, but not CLL. In our study, the association with body size appeared to be stronger for CML but, due to small numbers, this supposition could not be verified. Furthermore, male U.S. veterans with a history of hospitalization for obesity have been found to be at increased risk of multiple myeloma, CLL, and AML (12).
Central adiposity increases the risk of several common epithelial cancers (21), and it has been hypothesized to be related to the consequent chronic hyperinsulinemia and an associated increase in circulating insulin like growth factor 1 (IGF-1) that stimulates cell proliferation and inhibits apoptosis (22). Growth factors, including IGF-1, have also been shown to be mitogenic in AML cell lines (23). Central obesity also increases circulating levels of leptin (24). Myeloid precursor cells in the bone marrow have both IGF and leptin receptors, and leptin is known to play a role in the modulation of the innate immune response, inflammation, and hematopoiesis (25). Obesity may also influence immune function (26,27), although little research comparing immune responses of lean and obese subjects has been reported (28). Nutritional alterations, such as fasting and acute nutritional deprivation, occur frequently in obese persons and can both increase and decrease immunocompetence (29).
In conclusion, we found that overall adiposity (including central) and nonadipose mass (or fat-free mass) were both associated with myeloid leukemia. However, they were not associated with any other lymphohematopoietic malignancies.
![]() |
NOTES |
---|
![]() ![]() ![]() ![]() |
---|
Cohort recruitment was funded by VicHealth and The Cancer Council Victoria. This study was funded by grants from the National Health and Medical Research Council (209057; 170215) and was further supported by infrastructure provided by The Cancer Council Victoria.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() |
---|
(1) Holly EA, Lele C, Bracci PM, McGrath MS. Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 1999;150:37589.[Abstract]
(2) Zhang S, Hunter DJ, Rosner BA, Colditz GA, Fuchs CS, Speizer FE, et al. Dietary fat and protein in relation to risk of non-Hodgkin's lymphoma among women. J Natl Cancer Inst 1999;91:17518.
(3) Friedman GD, Herrinton LJ. Obesity and multiple myeloma. Cancer Causes Control 1994;5:47983.[CrossRef][ISI][Medline]
(4) Tulinius H, Sigfusson N, Sigvaldason H, Bjarnadottir K, Tryggvadottir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev 1997;6:86373.[Abstract]
(5) Cerhan JR, Janney CA, Vachon CM, Habermann TM, Kay NE, Potter JD, et al. Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. Am J Epidemiol 2002;156:52735.
(6) Ross JA, Parker E, Blair CK, Cerhan JR, Folsom AR. Body mass index and risk of leukemia in older women. Cancer Epidemiol Biomarkers Prev 2004;13:18103.
(7) Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:162538.
(8) Moller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994;30A:34450.[CrossRef]
(9) Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001;12:1321.[CrossRef][ISI][Medline]
(10) Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y. Association of obesity and cancer risk in Canada. Am J Epidemiol 2004;159:25968.
(11) Davey Smith G, Hart C, Upton M, Hole D, Gillis C, Watt G, et al. Height and risk of death among men and women: aetiological implications of associations with cardiorespiratory disease and cancer mortality. J Epidemiol Community Health 2000;54:97103.
(12) Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni JF Jr. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 2004;15:3543.[CrossRef][ISI][Medline]
(13) Chang ET, Hjalgrim H, Smedby KE, Akerman M, Tani E, Johnsen HE, et al. Body mass index and risk of malignant lymphoma in Scandinavian men and women. J Natl Cancer Inst 2005;97:2108.
(14) Giles GG. The Melbourne study of diet and cancer. Proc Nutr Soc Aust 1990;15:618.
(15) MacInnis RJ, English DR, Gertig DM, Hopper JL, Giles GG. Body size and composition and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:211725.
(16) MacInnis RJ, English DR, Gertig DM, Hopper JL, Giles GG. Body size and composition and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:141721.
(17) Lohman TG, Roche AF, Martorell R. Anthropometric standardization reference manual. Champaign (IL): Kinetics Books; 1988.
(18) Roubenoff R, Baumgartner RN, Harris TB, Dallal GE, Hannan MT, Economos CD, et al. Application of bioelectrical impedance analysis to elderly populations. J Gerontol A Biol Sci Med Sci 1997;52:M12936.[ISI][Medline]
(19) Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997;145:7280.[Abstract]
(20) Collett D. Modelling survival data in medical research. Boca Raton (FL): Chapman & Hall/CRC; 1999.
(21) MacInnis RJ, English DR, Hopper JL, Haydon AM, Gertig DM, Giles GG. Body size and composition and colon cancer risk in men. Cancer Epidemiol Biomarkers Prev 2004;13:5539.
(22) McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 1994;3:68795.[Abstract]
(23) Shimon I, Shpilberg O. The insulin-like growth factor system in regulation of normal and malignant hematopoiesis. Leuk Res 1995;19:23340.[CrossRef][ISI][Medline]
(24) Soderberg S, Olsson T, Eliasson M, Johnson O, Brismar K, Carlstrom K, et al. A strong association between biologically active testosterone and leptin in non-obese men and women is lost with increasing (central) adiposity. Int J Obes Relat Metab Disord 2001;25:98105.[CrossRef][Medline]
(25) Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2000;68:43746.
(26) Stallone DD. The influence of obesity and its treatment on the immune system. Nutr Rev 1994;52:3750.[ISI][Medline]
(27) Chandra RK. Nutrition and the immune system: an introduction. Am J Clin Nutr 1997;66:460S3S.[Abstract]
(28) Marti A, Marcos A, Martinez JA. Obesity and immune function relationships. Obes Rev 2001;2:13140.[CrossRef][Medline]
(29) Wing EJ, Stanko RT, Winkelstein A, Adibi SA. Fasting-enhanced immune effector mechanisms in obese subjects. Am J Med 1983;75:916.[Medline]
(30) Vainio H, Bianchini F, editors. IARC handbooks of cancer prevention, Vol. 6: Weight control and physical activity. Lyon (France): IARC Press; 2002.
(31) Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995;311:15861.
(32) Molarius A, Seidell JC, Sans S, Tuomilehto J, Kuulasmaa K. Varying sensitivity of waist action levels to identify subjects with overweight or obesity in 19 populations of the WHO MONICA Project. J Clin Epidemiol 1999;52:121324.[CrossRef][ISI][Medline]
Manuscript received December 22, 2004; revised May 23, 2005; accepted May 26, 2005.
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |